A detailed history of Herold Advisors, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Herold Advisors, Inc. holds 39,149 shares of ABBV stock, worth $7.58 Million. This represents 1.59% of its overall portfolio holdings.

Number of Shares
39,149
Previous 38,345 2.1%
Holding current value
$7.58 Million
Previous $6.98 Million 3.84%
% of portfolio
1.59%
Previous 1.72%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$154.79 - $180.76 $124,451 - $145,331
804 Added 2.1%
39,149 $6.71 Million
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $69,202 - $78,849
-433 Reduced 1.12%
38,345 $6.98 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $93,843 - $105,689
682 Added 1.79%
38,778 $6.01 Million
Q3 2023

Nov 08, 2023

BUY
$133.59 - $154.65 $343,059 - $397,141
2,568 Added 7.23%
38,096 $5.68 Million
Q2 2023

Jul 14, 2023

BUY
$132.51 - $164.9 $206,450 - $256,914
1,558 Added 4.59%
35,528 $4.79 Million
Q1 2023

Apr 19, 2023

BUY
$144.61 - $166.54 $5,495 - $6,328
38 Added 0.11%
33,970 $5.41 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $212,167 - $254,444
1,534 Added 4.73%
33,932 $5.49 Million
Q3 2022

Nov 08, 2022

BUY
$134.21 - $153.93 $38,786 - $44,485
289 Added 0.9%
32,398 $4.35 Million
Q2 2022

Jul 15, 2022

BUY
$137.62 - $174.96 $36,331 - $46,189
264 Added 0.83%
32,109 $4.92 Million
Q1 2022

May 09, 2022

BUY
$131.98 - $163.75 $154,812 - $192,078
1,173 Added 3.82%
31,845 $5.16 Million
Q4 2021

Jan 20, 2022

SELL
$107.43 - $135.93 $15,147 - $19,166
-141 Reduced 0.46%
30,672 $4.15 Million
Q3 2021

Nov 03, 2021

BUY
$106.4 - $120.78 $3.28 Million - $3.72 Million
30,813 New
30,813 $3.32 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Herold Advisors, Inc. Portfolio

Follow Herold Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Herold Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Herold Advisors, Inc. with notifications on news.